Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carborane Hydrophobic Tags Drive Selective Degradation of Endogenous KRAS<sup>G12C</sup> via HSP70-Ubiquitin-Proteasome Pathway.

ACS bio & med chem Au·2026
Same author

Transporter-Associated Therapeutic Efficacy of an SMVT-Targeted Boron Carrier in Boron Neutron Capture Therapy.

Cancer science·2026
Same author

Recent Advances in Photocatalyst-Driven Protein Labeling and Proximity Mapping.

Chemical record (New York, N.Y.)·2026
Same author

Facet-Selective Growth of Heterostructured Molecular Crystals Enabled by a Solid-Solution-Mediated Strategy.

JACS Au·2026
Same author

Correction to "Dimensionality Reduction of Formamidinium-Rich Lead Iodide Perovskite-Derived Structures".

Journal of the American Chemical Society·2026
Same author

Molecular dynamics insights into orientation and hexagonal ordering of tripodal triptycenes on solid surfaces.

Nanoscale horizons·2026

Related Experiment Video

Updated: May 16, 2025

One Minute, Sub-One-Watt Photothermal Tumor Ablation Using Porphysomes, Intrinsic Multifunctional Nanovesicles
09:51

One Minute, Sub-One-Watt Photothermal Tumor Ablation Using Porphysomes, Intrinsic Multifunctional Nanovesicles

Published on: September 17, 2013

10.7K

BODIPY-Based Photothermal Agent Incorporating Azulene for Enhanced NIR Absorption and Tumor Ablation.

Kai Nishimura1, Mikiya Kato2, Tomoya Fukui2,3,4

  • 1School of Life Science and Technology, Institute of Science Tokyo, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan.

Molecular Pharmaceutics
|April 1, 2025
PubMed
Summary

A new photothermal agent, AzuGlu-BODIPY, shows high efficiency and stability for cancer treatment. This novel agent achieved complete tumor regression in mice, offering a promising alternative to current therapies.

Keywords:
azulenenear-infraredphotothermal agentphotothermal therapy

More Related Videos

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
09:01

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Published on: May 22, 2020

3.0K
Plasmonic Photothermal Cancer Therapy: Nanoparticle-embedded Tumor-tissue-mimicking Phantoms for Visualizing Photothermal Temperature Distribution
06:50

Plasmonic Photothermal Cancer Therapy: Nanoparticle-embedded Tumor-tissue-mimicking Phantoms for Visualizing Photothermal Temperature Distribution

Published on: May 9, 2025

107

Related Experiment Videos

Last Updated: May 16, 2025

One Minute, Sub-One-Watt Photothermal Tumor Ablation Using Porphysomes, Intrinsic Multifunctional Nanovesicles
09:51

One Minute, Sub-One-Watt Photothermal Tumor Ablation Using Porphysomes, Intrinsic Multifunctional Nanovesicles

Published on: September 17, 2013

10.7K
Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
09:01

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Published on: May 22, 2020

3.0K
Plasmonic Photothermal Cancer Therapy: Nanoparticle-embedded Tumor-tissue-mimicking Phantoms for Visualizing Photothermal Temperature Distribution
06:50

Plasmonic Photothermal Cancer Therapy: Nanoparticle-embedded Tumor-tissue-mimicking Phantoms for Visualizing Photothermal Temperature Distribution

Published on: May 9, 2025

107

Area of Science:

  • Materials Science
  • Biomedical Engineering
  • Chemistry

Background:

  • Photothermal therapy (PTT) utilizes light energy for localized tumor ablation.
  • Current photothermal agents like Indocyanine green (ICG) have limitations including photobleaching and poor tumor retention.
  • Development of advanced photothermal agents (PTAs) is crucial for effective PTT.

Purpose of the Study:

  • To develop and evaluate AzuGlu-BODIPY, a novel azulene-based BODIPY derivative, as an improved PTA.
  • To assess the photothermal conversion efficiency (PCE), stability, and efficacy of AzuGlu-BODIPY.
  • To investigate the potential of AzuGlu-BODIPY for cancer treatment via PTT.

Main Methods:

  • Synthesis and characterization of AzuGlu-BODIPY, a BODIPY-based PTA with azulene, tetrahydroquinoline, and glucose components.
  • Evaluation of photothermal conversion efficiency (PCE) and thermal stability in various solutions.
  • In vitro cytotoxicity assays against cancer cell lines under 808 nm laser irradiation.
  • In vivo studies using 4T1 tumor-bearing mice to assess tumor regression after localized administration and laser treatment.

Main Results:

  • AzuGlu-BODIPY exhibited a high PCE of 51%, strong near-infrared (NIR) absorption, and excellent thermal stability.
  • In vitro studies demonstrated potent photothermal efficacy with IC50 values ranging from 3.1-4.6 μM.
  • In vivo experiments resulted in complete tumor regression in mice treated with AzuGlu-BODIPY and laser irradiation.

Conclusions:

  • AzuGlu-BODIPY represents a promising next-generation PTA with superior properties compared to existing agents.
  • The developed agent shows significant potential for effective cancer ablation through PTT.
  • This study provides a versatile platform for designing advanced azulene-based PTAs for enhanced therapeutic functionality.